In addition to joining Calidi’s Board of Directors in July 2020, James A. “Jim” Schoeneck has been a member of the Board at Fibrogen, Inc. since April 2010, currently serving as Chairman of the Board and as Interim CEO in 2019 and 2020. Prior, he joined the Board of Depomed, Inc. in 2007, then served as CEO from 2011 to 2017, leading the transformation into a commercial specialty pharmaceutical company. From 2005 until 2011, he was CEO of BrainCells Inc., a privately-held biopharmaceutical company. Before joining BrainCells, Inc., Schoeneck served as CEO of ActivX BioSciences, a development-stage biotechnology company. His diverse biotech experience further includes three years as President and CEO of Prometheus Laboratories Inc., a pharmaceutical and diagnostics product company, as well as three years as Vice President and General Manager, Immunology, at Centocor, Inc.—now Janssen Biotech, Inc. At Centocor, Schoeneck led the development of the biotechnology company’s commercial capabilities and oversaw the launch of Remicade®, which became one of the world’s largest pharmaceutical brands. Earlier in his career, he spent 13 years at pharmaceutical company Rhone-Poulenc Rorer, Inc.—now Sanofi—serving in various sales and marketing positions of increasing responsibility. Schoeneck holds a BS in Education from Jacksonville State University.
James A. Schoeneck
Board Member — Appointed July 2020